01—Abstract
Summary
Summary of the 8-K filed May 29, 2026. Cited figures are marked; the original filing is the authoritative source.
Cencora, Inc. (NYSE: COR) filed an 8-K on May 29, 2026 announcing that Eva C.
Boratto has been appointed Executive Vice President and Chief Financial Officer, effective June 29, 2026. She succeeds James F. Cleary, who is retiring; he will serve in an advisory capacity through the end of 2026 to support the transition.
Ms. Boratto most recently served as CFO of Bath & Body Works (since August 2023) and previously spent 12 years at CVS Health, including as EVP and CFO, plus roughly 20 years at Merck & Co. Her background in large-scale finance and public-company governance (she chairs audit committees at Mars, Inc. and United Parcel Service) is a relevant credential for a company of Cencora's scale. Compensation terms are substantial but largely standard for a senior executive hire. Her base salary is $1,000,000a with a 100% target annual bonus, and she is eligible for the same long-term and short-term incentive programs as other executive officers.
She also receives a one-time $2,000,000b cash sign-on bonus, subject to repayment on resignation or termination for cause within one year, and a one-time RSU award valued at $6,000,000 vesting ratably over three years. The filing also includes her employment agreement and standard indemnification agreement. Investors should note that the CFO transition itself is a routine but meaningful leadership change, and the sign-on and equity grants represent modest near-term dilution and expense rather than a material change to the financial outlook.
In a separate Regulation FD disclosure (Item 7.01, furnished rather than filed), Cencora reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.70 to $17.90c and its long-term targets of 7% to 10% adjusted operating income growth and 10% to 14% adjusted diluted EPS growth. The company noted that on May 21, 2026 it had raised the low end of its FY2026 EPS range from $17.65 due to opportunistic share repurchases completed in May. The reaffirmation of guidance alongside the leadership change is likely intended to signal continuity in strategy and financial execution during the transition.
02—Key points
Key Highlights
- Eva C. Boratto appointed EVP and Chief Financial Officer effective June 29, 2026, succeeding retiring CFO James F. Cleary, who will advise through year-end 2026.
- Boratto brings extensive public-company finance experience, including prior CFO roles at Bath & Body Works and CVS Health, and about 20 years at Merck & Co.
- Compensation includes a $1,000,000 base salary, a 100% target bonus, a one-time $2,000,000 cash sign-on bonus (with one-year clawback provisions), and a one-time $6,000,000 RSU grant vesting over three years.
- Cencora reaffirmed FY2026 adjusted diluted EPS guidance of $17.70 to $17.90, following an upward adjustment of the low end on May 21, 2026 tied to opportunistic May share repurchases.
- Long-term targets were reaffirmed: adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%.
- Boratto's employment agreement follows the company's standard executive form and includes change-in-control and severance provisions as well as non-compete and confidentiality terms.
- The Item 7.01 disclosure is furnished, not filed, meaning it is not subject to Section 18 liability under the Exchange Act.
03—Questions
Frequently Asked Questions
Why is Cencora changing its CFO, and is the transition planned?
The change was planned. James F. Cleary is retiring as EVP and CFO, and he will remain in an advisory capacity through the end of 2026 to help ensure a smooth handoff to Eva Boratto, who takes over on June 29, 2026.
What is Eva Boratto's relevant financial background?
She was CFO of Bath & Body Works from August 2023, CFO of Opentrons Labwork from 2022 to 2023, and spent 12 years at CVS Health, most recently as EVP and CFO (2018 to 2021). She also spent about 20 years at Merck & Co. in finance and investor relations leadership roles. She chairs the audit committees of Mars, Inc. and United Parcel Service.
How significant is her compensation package for investors?
The package is substantial but not unusual for a large-cap CFO. It includes a $1,000,000 base salary, a 100% target bonus, a one-time $2,000,000 cash sign-on bonus subject to repayment if she leaves within one year, and a $6,000,000 RSU award vesting over three years. The equity grant adds modest dilution and stock-based compensation expense over the vesting period.
Did Cencora change its financial outlook with this announcement?
No. Cencora reaffirmed its FY2026 adjusted diluted EPS guidance of $17.70 to $17.90 and its long-term targets of 7% to 10% adjusted operating income growth and 10% to 14% adjusted diluted EPS growth. The guidance low end had already been raised on May 21, 2026, reflecting share repurchases completed in May.
Does the announcement signal any operational concerns?
The filing does not indicate any operational concerns or reasons for the change beyond the planned retirement of Mr. Cleary. The reaffirmation of guidance alongside the leadership announcement suggests management intends to signal continuity, though investors should monitor the upcoming quarterly results for the new CFO's early commentary.
04—Continue